PDE

シグナル伝達経路

研究分野

阻害剤の選択性比較

カタログ番号	製品カタログ	溶解度(25°C)
カタログ番号	製品カタログ	水	DMSO	アルコール
S2131	Roflumilast	<1 mg/mL	81 mg/mL	15 mg/mL
S1431	Sildenafil Citrate	<1 mg/mL	20 mg/mL	<1 mg/mL
S1512	Tadalafil	<1 mg/mL	78 mg/mL	<1 mg/mL
S2515	Vardenafil HCl Trihydrate	10 mg/mL	100 mg/mL	20 mg/mL
S1550	Pimobendan	<1 mg/mL	67 mg/mL	5 mg/mL
S6576	BW-A78U	<1 mg/mL	51 mg/mL	26 mg/mL
S6433	Udenafil	<1 mg/mL	100 mg/mL	25 mg/mL
S2620	GSK256066	<1 mg/mL	5 mg/mL	<1 mg/mL
S2687	PF-2545920	<1 mg/mL	78 mg/mL	78 mg/mL
S1430	Rolipram	<1 mg/mL	55 mg/mL	55 mg/mL
S8034	Apremilast (CC-10004)	<1 mg/mL	92 mg/mL	<1 mg/mL
S1294	Cilostazol	<1 mg/mL	74 mg/mL	6 mg/mL
S2484	Milrinone	<1 mg/mL	42 mg/mL	<1 mg/mL
S4019	Avanafil	<1 mg/mL	97 mg/mL	<1 mg/mL
S2127	S- (+)-Rolipram	<1 mg/mL	55 mg/mL	55 mg/mL
S1673	Aminophylline	84 mg/mL	53 mg/mL	<1 mg/mL
S3172	Anagrelide HCl	<1 mg/mL	14 mg/mL	<1 mg/mL
S1504	Dyphylline	51 mg/mL	51 mg/mL	<1 mg/mL
S1895	Dipyridamole	<1 mg/mL	101 mg/mL	50 mg/mL
S4164	Doxofylline	24 mg/mL	53 mg/mL	2 mg/mL
S4090	Fenspiride HCl	59 mg/mL	9 mg/mL	<1 mg/mL
S4837	Ibudilast	30 mg/mL	46 mg/mL	46 mg/mL
S7224	Deltarasin	<1 mg/mL	100 mg/mL	100 mg/mL
S5806	Cilostamide	<1 mg/mL	6 mg/mL	5 mg/mL
S8459	TAK-063	<1 mg/mL	85 mg/mL	<1 mg/mL
S2291	Diosgenin	<1 mg/mL	<1 mg/mL	5 mg/mL
S2312	Icariin	<1 mg/mL	50 mg/mL	<1 mg/mL
S4683	Sildenafil Mesylate	100 mg/mL	100 mg/mL	4 mg/mL
S4684	Sildenafil	14 mg/mL	<1 mg/mL	<1 mg/mL
S2320	Luteolin	<1 mg/mL	57 mg/mL	3 mg/mL
S8218	PF-8380	<1 mg/mL	95 mg/mL	<1 mg/mL
S5836	IBMX	<1 mg/mL	44 mg/mL	7 mg/mL
S9436	Pinoresinol dimethyl ether	-1 mg/mL	77 mg/mL	-1 mg/mL
S5837	BRL-50481	<1 mg/mL	49 mg/mL	49 mg/mL
S2368	Theobromine	<1 mg/mL	<1 mg/mL	<1 mg/mL
S9229	Linderane	-1 mg/mL	52 mg/mL	-1 mg/mL

亜型選択性的な製品

PDE製品

All (36) PDE阻害剤(35) PDE活性剤(1) 新PDE製品

製品コード	製品説明	文献中Selleckの製品使用例	お客様のフィードバック
S2131	Roflumilast Roflumilast is a selective inhibitor of PDE4 with IC50 of 0.2-4.3 nM in a cell-free assay.	PLoS Negl Trop Dis, 2017, 11(7):e0005680 J Pharmacol Exp Ther, 2016, 357(1):66-72 Int Immunopharmacol, 2016, 35:174-84	Mean plasma concentration versus time after single dose oral administration of IC87114 and RFM in wistar rats( n = 6).
S1431	Sildenafil Citrate Sildenafil Citrate, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5), is a well-tolerated and highly effective treatment for erectile dysfunction.	Cancer Lett, 2016, 370(2):279-85 J Cell Physiol, 2016, 231(10):2286-302 Pharm Dev Technol, 2016, 21(8):961-971	T24 cells were treated with vehicle, SIL (2 uM), DOX (200 nM) as indicated. Cells were isolated 6 and 12 hours after exposure, and the phosphorylation of γH2AX was determined, with the fold increase in phosphorylation shown.
S1512	Tadalafil Tadalafil is a PDE-5 inhibitor with IC50 of 1.8 nM in a cell-free assay. Tadalafil is at least 9000 times more selective for PDE5 than most of the other families of PDEs, with the exception of PDE11. It can partial inhibits PDE11	J Clin Invest, 2019, 129(6):2318-2332 J Hepatol, 2018, 10.1016/j.jhep.2018.10.040 Invest Ophthalmol Vis Sci, 2017, 58(13):5604-5615	β-Catenin levels in 293T cells treated with PDE5 inhibitor in the presence or absence of Wnt3a. (a) Tadalafil reduced β-catenin protein levels. Immunofluorescence and confocal images of 293T cells treated with dimethyl sulfoxide (DMSO) or tadalafil at 10 uM in the presence or absence of recombinant Wnt3a for 24 h.
S2515	Vardenafil HCl Trihydrate Vardenafil HCl Trihydrate is a new type PDE inhibitor with IC50 of 0.7 and 180 nM for PDE5 and PDE1, respectively.	Invest Ophthalmol Vis Sci, 2017, 58(13):5604-5615 Oncotarget, 2017, 8(5):8574-8589 Cancer Lett, 2016, 378(1):38-50	(G) Immunoblot analysis for TAZ and Nanog in PCSC after vardenafil treatments. (H) Cytotoxicity to DDP in PCSC treated with indicated concentrations of vardenafil. *p < 0.01, p < 0.05 versus PC3 cells, vardenafil at 0 μM, or DDP at 0 μM; ++p < 0.01, +p < 0.05 versus vardenafil at 0 μM.
S1550	Pimobendan Pimobendan is a selective inhibitor of PDE3 with IC50 of 0.32 μM.	Cell Syst, 2019, 8(2):97-108
S6576^新	BW-A78U BW-A78U, an adenine derivative PDE inhibitor, has anticonvulsant activity.
S6433^新	Udenafil Udenafil is a potent antagonist of human PDE5 with an IC50 of 8.25 nM and a comparable selectivity profile as sildenafil for the other PDEs.
S2620	GSK256066 GSK256066 is a selective PDE4B(equal affinity to isoforms A-D) inhibitor with IC50 of 3.2 pM, >380,000-fold selectivity versus PDE1/2/3/5/6 and >2500-fold selectivity against PDE4B versus PDE7.Phase 2.
S2687	PF-2545920 PF-2545920 is a potent and selective PDE10A inhibitor with IC50 of 0.37 nM, with >1000-fold selectivity over the PDE.	Front Mol Neurosci, 2017, 10:100 Am J Hum Genet, 2017, 100(1):5-20 EMBO Mol Med, 2016, 8(7):796-812
S1430	Rolipram The PDE4 selective inhibitor, rolipram, inhibited immunopurified PDE4B and PDE4D activities similarly, with IC50 values of approx. 130 nM and 240 nM respectively; an anti-inflammatory agent.	Biomed Pharmacother, 2018, 99:947-955 Neurochem Res, 2018, 43(4):785-795 Mol Nutr Food Res, 2017, 10.1002/mnfr.201600966	D, average percentage difference of cell growth by PDE4D inhibitors between STK11 mutant and wild-type cell lines. The sensitivity on STK11mt cell lines represents the difference of average percentage growth between STK11-mutant (NCI-H1993 and NCI-H1395) and wild-type cell lines (NCI-H82 and NCI-H524). Average percentage growth of each cell line by a PDE4D inhibitor was based on the DMSO control. Cells were treated with a 20 μmol/L of PDE4D inhibitors for 3, 7, and 10 days incubation, respectively. The cell viability was determined using CellTiter-Blue fluorescence. , P < 0.01 and *, P < 0.05 in the difference between STK11-mutant and wild-type cell lines. All cells used in the experiment were cultured in normal conditioned RPMI medium with 10% FBS and 1% penicillin/streptavidin.
S8034	Apremilast (CC-10004) Apremilast (CC-10004) is a potent and orally active PDE4 and TNF-α inhibitor with IC50 of 74 nM and 77 nM, respectively.	Pharmacol Res, 2018, 128:244-251
S1294	Cilostazol Cilostazol is a potent cyclic nucleotide phosphodiesterase type 3 (PDE3) inhibitor with IC50 of 0.2 μM and inhibitor of adenosine uptake.	Mol Cell, 2019, 75(6):1103-1116.e9 FASEB J, 2019, 10.1096/fj.201900326R
S2484	Milrinone Milrinone is a phosphodiesterase 3 (PDE3) inhibitor, used to increase the heart's contractility.	Biochem Biophys Res Commun, 2018, 503(3):1409-1414 Mol Pharm, 2017, 10.1021/acs.molpharmaceut.7b00360	Viability of H9c2 cells incubated with MRN-HSA-NPs (black bars) compared with MRN-Lactate (grey bars) at different MRN concentrations, at (a) 4 hours, (b) 24 hours and (c) 48 hours. The graph shows a representative result of mean±SD (n=3). **P<0.0001, P<0.001, P<0.01 and P<0.05 were considered significant based on Sidak’s posthoc analysis.
S4019	Avanafil Avanafil is a highly selective PDE5 inhibitor with IC50 of 5.2 nM, >121-fold selectivity over other PDEs.
S2127	S- (+)-Rolipram S-(+)-Rolipram inhibits human monocyte cyclic AMP-specific PDE4 with IC50 of 0.75 μM, has anti-inflammatory and anti-depressant activity in the central nervous system, less potent than its R enantiomer.	Viruses, 2019, 11(12)
S1673	Aminophylline Aminophylline is a competitive nonselective phosphodiesterase inhibitor with an IC50 of 0.12 mM and also a nonselective adenosine receptor antagonist.
S3172	Anagrelide HCl Anagrelide is a drug used for the treatment of essential thrombocytosis.
S1504	Dyphylline Dyphylline is a xanthine derivative with bronchodilator and vasodilator effects.	Biogerontology, 2016, 17(5-6):907-920
S1895	Dipyridamole Dipyridamole (Persantine) is a phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells.	Am J Hum Genet, 2017, 100(1):5-20
S4164	Doxofylline Doxofylline is a phosphodiesterase inhibitor and a xanthine derivative drug for asthma.
S4090	Fenspiride HCl Fenspiride is a bronchodilator with anti-inflammatory properties, inhibiting phosphodiesterase 4 and phosphodiesterase 3 activities with logIC50 values of 4.16 and 3.44, respectively, in human isolated bronchi.
S4837	Ibudilast Ibudilast is a relatively non-selective phosphodiesterase inhibitor with anti-inflammatory and neuroprotective activities.
S7224	Deltarasin Deltarasin is a small molecular inhibitor of KRAS-PDEδ interaction with K_d of 38 nM for binding to purified PDEδ.	Cell Death Differ, 2019, 26(11):2400-2415 Acta Pharmacol Sin, 2019, 10.1038/s41401-019-0268-y Nat Commun, 2018, 9(1):672
S5806	Cilostamide Cilostamide is an inhibitor of type III phosphodiesterases with IC50 values of 27 nM and 50 nM for PDE3A and PDE3B, respectively.
S8459	TAK-063 TAK-063 is a novel and selective phosphodiesterase 10A(PDE10A) inhibitor with an IC50 of 0.30 nM.
S2291	Diosgenin Diosgenin is a steroid sapogenin and the precursor for the semisynthesis of progesterone which in turn was used in early combined oral contraceptive pills; A weak PDE inhibitor.
S2312	Icariin Icariin is a cGMP-specific PDE5 inhibitor with IC50 of 0.432 μM, 167-fold more selective for PDE5 than PDE4.	Shandong University, 2014, Haoran Cui
S4683	Sildenafil Mesylate Sildenafil Mesylate is a mesylate form of Sildenafil, an inhibitor of Phosphodiesterase 5.
S4684	Sildenafil Sildenafil is a Phosphodiesterase 5 Inhibitor with IC50 of 5.22 nM.	J Cell Physiol, 2019, 234(4):4874-4887 Anticancer Res, 2018, 38(9):5149-5157 Cancer Biol Ther, 2018, 10.1080/15384047.2018.1507665	mRNA and protein expression levels of Id‑1 following treatment with 5 μM sildenafil for 24 h. (A) Relative mRNA expression levels of Id‑1 in the HemECs were significantly decreased by 44.2%, according to the 2‑ΔΔCq method (***P=0.0006 vs. control). (B) Western blotting revealed that the protein expression levels of Id‑1 markedly decreased following treatment with sildenafil when compared with the negative control. The TCA 8113 cell line was used as a positive control. HemECs, hemangioma endothelial cells; SIL, sildenafil; ID‑1, inhibitor of differentiation 1.
S2320	Luteolin Luteolin is a flavonoid found in Terminalia chebula, which is a non-selective phisphodiesterase PDE inhibitor for PDE1-5 with Ki of 15.0 μM, 6.4 μM, 13.9 μM, 11.1 μM and 9.5 μM, respectively. Phase 2.	Eur J Pharmacol, 2020, 873:172981 Mol Ther, 2019, 27(5):1039-1050 Mol Ther, 2019, 27(5):1039-1050	Bioactive compounds inhibit recombinant HDAC activity. Recombinant HDACs were incubated with flavonoid Luteolin (C) for 2 h prior to the addition of cell permeable HDAC substrates. Luteolin inhibited activity of most classes I, IIa, and IIb HDAC isoforms.
S8218	PF-8380 PF-8380 is a potent autotaxin inhibitor with IC50 of 2.8nM in an in vitro enzyme assay.
S5836	IBMX Isobutylmethylxanthine (IBMX) is a nonspecific inhibitor of phosphodiesterase (PDE) with IC50 values of 6.5±1.2, 26.3±3.9 and 31.7±5.3 μM for PDE3, 4 and 5 respectively. It may enhance the intracellular cAMP levels and also acts as an adenosine (A1) receptor antagonist.	Sci Signal, 2016, 9(430):ra56
S9436	Pinoresinol dimethyl ether Pinoresinol dimethyl ether, which could be isolated from the wood of the basal tree Humbertieae, show a variety of activities as the inhibitor of cyclic AMP phosphodiesterase.
S5837	BRL-50481 BRL-50481 is a novel and selective inhibitor of phosphodiesterase (PDE) 7 with a Ki value, derived from secondary (Dixon) plots, of 180±10 nM, being at least 200-fold selective for hrPDE7A1 over all other PDEs.
S2368	Theobromine Theobromine is a xanthine alkaloid widely consumed as stimulants and snacks in coffee and cocoa based foods and most often as part of ingredients in drugs.
S9229	Linderane Linderane, isolated from Lindera strychnifolia vill., is an indirect PDE3 activator and possesses multiple biological effects, including superoxide anion radical-scavenging and antioxidative activity and protective activity against gastritis, gastric ulcers and backache.

製品コード	製品説明	文献中Selleckの製品使用例	お客様のフィードバック
S2131	Roflumilast Roflumilast is a selective inhibitor of PDE4 with IC50 of 0.2-4.3 nM in a cell-free assay.	PLoS Negl Trop Dis, 2017, 11(7):e0005680 J Pharmacol Exp Ther, 2016, 357(1):66-72 Int Immunopharmacol, 2016, 35:174-84	Mean plasma concentration versus time after single dose oral administration of IC87114 and RFM in wistar rats( n = 6).
S1431	Sildenafil Citrate Sildenafil Citrate, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5), is a well-tolerated and highly effective treatment for erectile dysfunction.	Cancer Lett, 2016, 370(2):279-85 J Cell Physiol, 2016, 231(10):2286-302 Pharm Dev Technol, 2016, 21(8):961-971	T24 cells were treated with vehicle, SIL (2 uM), DOX (200 nM) as indicated. Cells were isolated 6 and 12 hours after exposure, and the phosphorylation of γH2AX was determined, with the fold increase in phosphorylation shown.
S1512	Tadalafil Tadalafil is a PDE-5 inhibitor with IC50 of 1.8 nM in a cell-free assay. Tadalafil is at least 9000 times more selective for PDE5 than most of the other families of PDEs, with the exception of PDE11. It can partial inhibits PDE11	J Clin Invest, 2019, 129(6):2318-2332 J Hepatol, 2018, 10.1016/j.jhep.2018.10.040 Invest Ophthalmol Vis Sci, 2017, 58(13):5604-5615	β-Catenin levels in 293T cells treated with PDE5 inhibitor in the presence or absence of Wnt3a. (a) Tadalafil reduced β-catenin protein levels. Immunofluorescence and confocal images of 293T cells treated with dimethyl sulfoxide (DMSO) or tadalafil at 10 uM in the presence or absence of recombinant Wnt3a for 24 h.
S2515	Vardenafil HCl Trihydrate Vardenafil HCl Trihydrate is a new type PDE inhibitor with IC50 of 0.7 and 180 nM for PDE5 and PDE1, respectively.	Invest Ophthalmol Vis Sci, 2017, 58(13):5604-5615 Oncotarget, 2017, 8(5):8574-8589 Cancer Lett, 2016, 378(1):38-50	(G) Immunoblot analysis for TAZ and Nanog in PCSC after vardenafil treatments. (H) Cytotoxicity to DDP in PCSC treated with indicated concentrations of vardenafil. *p < 0.01, p < 0.05 versus PC3 cells, vardenafil at 0 μM, or DDP at 0 μM; ++p < 0.01, +p < 0.05 versus vardenafil at 0 μM.
S1550	Pimobendan Pimobendan is a selective inhibitor of PDE3 with IC50 of 0.32 μM.	Cell Syst, 2019, 8(2):97-108
S6576^新	BW-A78U BW-A78U, an adenine derivative PDE inhibitor, has anticonvulsant activity.
S6433^新	Udenafil Udenafil is a potent antagonist of human PDE5 with an IC50 of 8.25 nM and a comparable selectivity profile as sildenafil for the other PDEs.
S2620	GSK256066 GSK256066 is a selective PDE4B(equal affinity to isoforms A-D) inhibitor with IC50 of 3.2 pM, >380,000-fold selectivity versus PDE1/2/3/5/6 and >2500-fold selectivity against PDE4B versus PDE7.Phase 2.
S2687	PF-2545920 PF-2545920 is a potent and selective PDE10A inhibitor with IC50 of 0.37 nM, with >1000-fold selectivity over the PDE.	Front Mol Neurosci, 2017, 10:100 Am J Hum Genet, 2017, 100(1):5-20 EMBO Mol Med, 2016, 8(7):796-812
S1430	Rolipram The PDE4 selective inhibitor, rolipram, inhibited immunopurified PDE4B and PDE4D activities similarly, with IC50 values of approx. 130 nM and 240 nM respectively; an anti-inflammatory agent.	Biomed Pharmacother, 2018, 99:947-955 Neurochem Res, 2018, 43(4):785-795 Mol Nutr Food Res, 2017, 10.1002/mnfr.201600966	D, average percentage difference of cell growth by PDE4D inhibitors between STK11 mutant and wild-type cell lines. The sensitivity on STK11mt cell lines represents the difference of average percentage growth between STK11-mutant (NCI-H1993 and NCI-H1395) and wild-type cell lines (NCI-H82 and NCI-H524). Average percentage growth of each cell line by a PDE4D inhibitor was based on the DMSO control. Cells were treated with a 20 μmol/L of PDE4D inhibitors for 3, 7, and 10 days incubation, respectively. The cell viability was determined using CellTiter-Blue fluorescence. , P < 0.01 and *, P < 0.05 in the difference between STK11-mutant and wild-type cell lines. All cells used in the experiment were cultured in normal conditioned RPMI medium with 10% FBS and 1% penicillin/streptavidin.
S8034	Apremilast (CC-10004) Apremilast (CC-10004) is a potent and orally active PDE4 and TNF-α inhibitor with IC50 of 74 nM and 77 nM, respectively.	Pharmacol Res, 2018, 128:244-251
S1294	Cilostazol Cilostazol is a potent cyclic nucleotide phosphodiesterase type 3 (PDE3) inhibitor with IC50 of 0.2 μM and inhibitor of adenosine uptake.	Mol Cell, 2019, 75(6):1103-1116.e9 FASEB J, 2019, 10.1096/fj.201900326R
S2484	Milrinone Milrinone is a phosphodiesterase 3 (PDE3) inhibitor, used to increase the heart's contractility.	Biochem Biophys Res Commun, 2018, 503(3):1409-1414 Mol Pharm, 2017, 10.1021/acs.molpharmaceut.7b00360	Viability of H9c2 cells incubated with MRN-HSA-NPs (black bars) compared with MRN-Lactate (grey bars) at different MRN concentrations, at (a) 4 hours, (b) 24 hours and (c) 48 hours. The graph shows a representative result of mean±SD (n=3). **P<0.0001, P<0.001, P<0.01 and P<0.05 were considered significant based on Sidak’s posthoc analysis.
S4019	Avanafil Avanafil is a highly selective PDE5 inhibitor with IC50 of 5.2 nM, >121-fold selectivity over other PDEs.
S2127	S- (+)-Rolipram S-(+)-Rolipram inhibits human monocyte cyclic AMP-specific PDE4 with IC50 of 0.75 μM, has anti-inflammatory and anti-depressant activity in the central nervous system, less potent than its R enantiomer.	Viruses, 2019, 11(12)
S1673	Aminophylline Aminophylline is a competitive nonselective phosphodiesterase inhibitor with an IC50 of 0.12 mM and also a nonselective adenosine receptor antagonist.
S3172	Anagrelide HCl Anagrelide is a drug used for the treatment of essential thrombocytosis.
S1504	Dyphylline Dyphylline is a xanthine derivative with bronchodilator and vasodilator effects.	Biogerontology, 2016, 17(5-6):907-920
S1895	Dipyridamole Dipyridamole (Persantine) is a phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells.	Am J Hum Genet, 2017, 100(1):5-20
S4164	Doxofylline Doxofylline is a phosphodiesterase inhibitor and a xanthine derivative drug for asthma.
S4090	Fenspiride HCl Fenspiride is a bronchodilator with anti-inflammatory properties, inhibiting phosphodiesterase 4 and phosphodiesterase 3 activities with logIC50 values of 4.16 and 3.44, respectively, in human isolated bronchi.
S4837	Ibudilast Ibudilast is a relatively non-selective phosphodiesterase inhibitor with anti-inflammatory and neuroprotective activities.
S7224	Deltarasin Deltarasin is a small molecular inhibitor of KRAS-PDEδ interaction with K_d of 38 nM for binding to purified PDEδ.	Cell Death Differ, 2019, 26(11):2400-2415 Acta Pharmacol Sin, 2019, 10.1038/s41401-019-0268-y Nat Commun, 2018, 9(1):672
S5806	Cilostamide Cilostamide is an inhibitor of type III phosphodiesterases with IC50 values of 27 nM and 50 nM for PDE3A and PDE3B, respectively.
S8459	TAK-063 TAK-063 is a novel and selective phosphodiesterase 10A(PDE10A) inhibitor with an IC50 of 0.30 nM.
S2291	Diosgenin Diosgenin is a steroid sapogenin and the precursor for the semisynthesis of progesterone which in turn was used in early combined oral contraceptive pills; A weak PDE inhibitor.
S2312	Icariin Icariin is a cGMP-specific PDE5 inhibitor with IC50 of 0.432 μM, 167-fold more selective for PDE5 than PDE4.	Shandong University, 2014, Haoran Cui
S4683	Sildenafil Mesylate Sildenafil Mesylate is a mesylate form of Sildenafil, an inhibitor of Phosphodiesterase 5.
S4684	Sildenafil Sildenafil is a Phosphodiesterase 5 Inhibitor with IC50 of 5.22 nM.	J Cell Physiol, 2019, 234(4):4874-4887 Anticancer Res, 2018, 38(9):5149-5157 Cancer Biol Ther, 2018, 10.1080/15384047.2018.1507665	mRNA and protein expression levels of Id‑1 following treatment with 5 μM sildenafil for 24 h. (A) Relative mRNA expression levels of Id‑1 in the HemECs were significantly decreased by 44.2%, according to the 2‑ΔΔCq method (***P=0.0006 vs. control). (B) Western blotting revealed that the protein expression levels of Id‑1 markedly decreased following treatment with sildenafil when compared with the negative control. The TCA 8113 cell line was used as a positive control. HemECs, hemangioma endothelial cells; SIL, sildenafil; ID‑1, inhibitor of differentiation 1.
S2320	Luteolin Luteolin is a flavonoid found in Terminalia chebula, which is a non-selective phisphodiesterase PDE inhibitor for PDE1-5 with Ki of 15.0 μM, 6.4 μM, 13.9 μM, 11.1 μM and 9.5 μM, respectively. Phase 2.	Eur J Pharmacol, 2020, 873:172981 Mol Ther, 2019, 27(5):1039-1050 Mol Ther, 2019, 27(5):1039-1050	Bioactive compounds inhibit recombinant HDAC activity. Recombinant HDACs were incubated with flavonoid Luteolin (C) for 2 h prior to the addition of cell permeable HDAC substrates. Luteolin inhibited activity of most classes I, IIa, and IIb HDAC isoforms.
S8218	PF-8380 PF-8380 is a potent autotaxin inhibitor with IC50 of 2.8nM in an in vitro enzyme assay.
S5836	IBMX Isobutylmethylxanthine (IBMX) is a nonspecific inhibitor of phosphodiesterase (PDE) with IC50 values of 6.5±1.2, 26.3±3.9 and 31.7±5.3 μM for PDE3, 4 and 5 respectively. It may enhance the intracellular cAMP levels and also acts as an adenosine (A1) receptor antagonist.	Sci Signal, 2016, 9(430):ra56
S9436	Pinoresinol dimethyl ether Pinoresinol dimethyl ether, which could be isolated from the wood of the basal tree Humbertieae, show a variety of activities as the inhibitor of cyclic AMP phosphodiesterase.
S5837	BRL-50481 BRL-50481 is a novel and selective inhibitor of phosphodiesterase (PDE) 7 with a Ki value, derived from secondary (Dixon) plots, of 180±10 nM, being at least 200-fold selective for hrPDE7A1 over all other PDEs.
S2368	Theobromine Theobromine is a xanthine alkaloid widely consumed as stimulants and snacks in coffee and cocoa based foods and most often as part of ingredients in drugs.

製品コード	製品説明	文献中Selleckの製品使用例	お客様のフィードバック
S9229	Linderane Linderane, isolated from Lindera strychnifolia vill., is an indirect PDE3 activator and possesses multiple biological effects, including superoxide anion radical-scavenging and antioxidative activity and protective activity against gastritis, gastric ulcers and backache.

製品コード

製品説明

文献中Selleckの製品使用例

お客様のフィードバック

S9229

Linderane

Linderane, isolated from Lindera strychnifolia vill., is an indirect PDE3 activator and possesses multiple biological effects, including superoxide anion radical-scavenging and antioxidative activity and protective activity against gastritis, gastric ulcers and backache.

研究分野別

製品類型

PDE

シグナル伝達経路

研究分野

阻害剤の選択性比較

亜型選択性的な製品

PDE製品